3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
195
Prostatic Neoplasms, Castration-Resistant
20
Neoplasm Metastasis
20
Metastatic Castration Resistant Prostate Cancer
10
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Metastatic Castration-resistant Prostate Cancer
6
Neoplasms
5
Castration-resistant Prostate Cancer
5
Breast Neoplasms
5
Pancreatic Neoplasms
4
Melanoma
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Prostate Adenocarcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Carcinoma, Renal Cell
3
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Prostatic Diseases
2
Ovarian Neoplasms
2
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Hormone Sensitive Prostate Cancer
2
Interventions
Peripheral Blood Stem Cell Transplantation
6
Cyclophosphamide
6
fludarabine phosphate
5
Nivolumab
5
Mycophenolic Acid
5
Carboplatin
5
Whole-Body Irradiation
4
Radiotherapy
4
Filgrastim
4
Cyclosporine
4
Gemcitabine
3
Cisplatin
3
Busulfan
3
Antilymphocyte Serum
3
cabozantinib
2
cabazitaxel
2
Voriconazole
2
Thiotepa
2
Therapeutics
2
Standard of Care
2
Sirolimus
2
Polymerase Chain Reaction
2
Mitomycin
2
Methylprednisolone
2
Methotrexate
2
Melphalan
2
Itraconazole
2
Immunoglobulin G
2
Goserelin
2
Flow Cytometry
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
enzalutamide
×
Genitourinary
×
Clear all
NCT06551324
2026-05-05
MEVPRO-1
Pfizer
Phase 3
Active not recruiting
600 enrolled